Evidence map›Paper›PMID 39893494›Full record

ArticleAlzheimer's research & therapy2025

Rotation errors in path integration are associated with Alzheimer's disease tau pathology: a cross-sectional study.

Lise Colmant, Lisa Quenon, Lara Huyghe, Adrian Ivanoiu, Thomas Gérard, Renaud Lhommel, Pauline Coppens, Yasmine Salman, Vincent Malotaux, Laurence Dricot and 4 more

Abstract read
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lise ColmantInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium. lise.colmant@uclouvain.be.
Lisa QuenonInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Lara HuygheInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Adrian IvanoiuInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Thomas GérardInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Renaud LhommelDepartment of Neurology, Cliniques Universitaires Saint-Luc, Brussels, 1200, Belgium.
Pauline CoppensInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Yasmine SalmanInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Vincent MalotauxInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Laurence DricotInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Lukas KunzDepartment of Epileptology, University Hospital Bonn, Bonn, 53127, Germany.
Nikolai AxmacherDepartment of Neuropsychology, Institute of Cognitive Neuroscience, Faculty of Psychology, Ruhr University Bochum, Bochum, 44780, Germany.
Philippe LefèvreInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.
Bernard HanseeuwInstitute of Neuroscience, NEUR, UCLouvain, Avenue Mounier 53/B1.53.05, Brussels, 1200, Belgium.

Funding

Fonds De La Recherche Scientifique - FNRS ASP40001844Fonds De La Recherche Scientifique - FNRS ASP40016560Fonds De La Recherche Scientifique - FNRS CCL40010417Fonds De La Recherche Scientifique - FNRS FRIA40014635Walloon excellence in life sciences and biotechnology 40010035
6 · The paper itself

Abstract

backgroundEarly Alzheimer's disease diagnosis is crucial for preventive therapy development. Standard neuropsychological evaluation does not identify clinically normal individuals with brain amyloidosis, the first stage of the pathology, defined as preclinical Alzheimer's disease. Spatial navigation assessment, in particular path integration, appears promising to detect preclinical symptoms, as the medial temporal lobe plays a key role in navigation and is the first cortical region affected by tau pathology.

methodsWe have conducted a cross-sectional study. We related the path integration performance of 102 individuals without dementia, aged over 50, to amyloid and tau pathologies, measured using positron emission tomography. We included 75 clinically normal individuals (19 with brain amyloidosis, 56 without) and 27 individuals with mild cognitive impairment (18 with brain amyloidosis, 9 without). We fitted linear mixed models to predict the path integration performances according to amyloid status or tau pathology in the medial temporal lobal, adjusting for age, gender, cognitive status, education, and video game experience. We decomposed the error into rotation and distance errors.

resultsWe observed that clinically normal adults with brain amyloidosis (preclinical Alzheimer's disease) had spatial navigation deficits when relying only on self-motion cues. However, they were able to use a landmark to reduce their errors. Individuals with mild cognitive impairment had deficits in path integration that did not improve when a landmark was added in the environment. The amyloid status did not influence performance among individuals with mild cognitive impairment. Among all individuals, rotation, but not distance, errors increased with the level of tau pathology in the medial temporal lobe.

conclusionOur results suggest that path integration performance in an environment without external cues allows identifying individuals with preclinical Alzheimer's disease, before overt episodic memory impairment is noticeable. Specifically, we demonstrated that poor angular estimation is an early cognitive marker of tau pathology, whereas distance estimation relates to older ages, not to Alzheimer's disease.

trial registrationEudra-CT 2018-003473-94.

Indexed as

Alzheimer DiseaseMovementtau ProteinsAgedAged, 80 and overAmyloidApolipoproteins ECognitive DysfunctionCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsAmyloidApoE protein, humanApolipoproteins Etau ProteinsAlzheimer’s diseaseEarly diagnosisPath integrationSpatial navigationTau pathology

Identifiers

PMID39893494
PMCPMC11786419

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.